GleamWall
中文EN

RDY DR REDDYS LABORATORIES LTD IFRS Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 1135951 · Reporting currency INR · Fiscal year ends 03/31

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY16.6%
TTM net income YoY1.5%
TTM EPS YoY1.5%
Revenue 3-yr CAGR14.9%
Net income 3-yr CAGR33.9%

Margins

Gross margin58.5%
Operating margin22.1%
Net margin17.4%
FCF margin5.8%
EBITDA margin27.3%

Returns

ROE18.4%
ROA12.8%
ROIC (approx.)16.3%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets31.6%
Debt / equity0.14x
Current ratio1.92x
Interest coverage25.40x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio2.3%
Payout ratio11.8%
Capex / revenue8.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: INR FY20252025-03-31FY20242024-03-31
Income statement
Revenue325.54B279.16B
Cost of revenue135.11B115.56B
Gross profit190.43B163.61B
R&D expense27.38B22.87B
SG&A expense93.87B77.20B
Operating income71.84B67.73B
Interest expense2.83B1.71B
Pretax income76.78B71.87B
Income tax19.54B16.19B
Net income56.54B55.68B
EBITDA88.90B82.57B
EPS (basic)67.8866.93
EPS (diluted)67.7866.80
Dividends declared per share40.0040.00
Weighted avg. shares (diluted)834.18M833.54M
Banking
Net interest income-152.00M567.00M
Balance sheet
Cash & equivalents14.65B7.11B
Short-term investments43.25B74.36B
Receivables90.42B80.30B
Inventory71.08B63.55B
Current assets250.11B248.05B
PP&E, netmay include right-of-use assets (IFRS)97.76B76.89B
Goodwill11.81B4.25B
Intangibles96.80B36.95B
Total assets492.99B387.52B
Current liabilities130.39B96.04B
Short-term debt38.05B12.72B
Long-term debt7.86B5.99B
Total debt45.91B18.71B
Total liabilities155.82B106.97B
Shareholders' equity333.39B280.55B
Net debt31.25B11.61B
Shares outstanding832.64M830.78M
Cash flow statement
Operating cash flow46.43B45.43B
Capital expenditure27.50B16.40B
Free cash flow18.92B29.03B
Investing cash flow-58.08B-40.28B
Financing cash flow18.91B-3.76B
Depreciation & amortization17.06B14.84B
Stock-based compensation424.00M407.00M
Dividends paid6.66B6.65B

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, INR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.